Ozempic vs Mounjaro: Two Separate FDA-Approved Medications

They are different molecules from different manufacturers, both FDA-approved for type 2 diabetes. Ozempic acts on the GLP-1 receptor; Mounjaro acts on both the GIP and GLP-1 receptors. Which one is appropriate for a given person is a clinical decision made by a licensed provider based on their individual health profile.

Ozempic contains semaglutide, a single-receptor GLP-1 agonist. Mounjaro contains tirzepatide, a dual GIP/GLP-1 receptor agonist that acts on two incretin pathways. Both molecules belong to the broader incretin-based class. Whether either approach is appropriate for an individual is determined by a licensed provider.

Any change between medications should occur under medical supervision, and Weight Method dispenses neither brand-name product. Whether a transition is appropriate and how dosing is managed is determined by a licensed provider based on your individual medical profile. Discuss timing and dose transitions during your Weight Method consultation.

The side effect profiles are similar — both commonly cause nausea, vomiting, diarrhea, and decreased appetite, especially during dose escalation. Individual responses vary. A licensed provider monitors tolerability for patients in Weight Method's compounded program.

Weight Method does not dispense or prescribe brand-name Ozempic® or Mounjaro®. Weight Method's compounded semaglutide program is $154/mo and compounded tirzepatide program is $329/mo, dispensed by U.S.-licensed 503A compounding pharmacies. Each is a flat monthly rate that includes the medication, licensed provider oversight, and shipping. Compounded medications are not FDA-approved.